生物技術 – 頁面 2 – BiotechEast Co., Ltd

Photo: Taiwan Bio-Industry Organization

BioBusiness Asia 2017 examines global trends, new technologies shaping healthcare

七月 7, 2017 davesilver 0 Comment

BioBusiness Asia, the two-day business-themed life sciences conference held annually in Taipei, Taiwan, recently concluded. A part of the week-long BioTaiwan festival of life science-focused events, the conference this year had a wide range of session themes with a particular emphasis on emerging technologies such as precision medicine, next generation sequencing, artificial intelligence (AI), synthetic biology, cancer immunotherapy, and digital health.

Photo: Insilico Medicine

焦點活動生物技術

Taiwan joins forces with Insilico Medicine to apply AI to biomedical research

七月 4, 2017 davesilver 0 Comment

The Development Center for Biotechnology (DCB), the Medical and Pharmaceutical Industrial Technology Development Center (PITDC), and Taipei Medical University (TMU), three of Taiwan’s premier biomedical institutions, have teamed up with Baltimore-based Insilico Medicine to develop groundbreaking research in applied A.I. for biomedical science.

生物技術製藥

AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera

六月 26, 2017 davesilver 0 Comment

AOP Orphan Pharmaceuticals AG of Vienna, Austria (AOP Orphan) and Taipei, Taiwan-headquartered PharmaEssentia Corporation (TPEx: 6446) together announced the latest results from three clinical studies on Ropeginterferon alfa-2b for patients with Polycythemia Vera (PV) presented at the 22nd Congress of the European Hematology Association (EHA) in Madrid, Spain.

Photo: Pixabay

生物技術製藥

Lumosa Therapeutics’ LT3001 for stroke receives FDA approval to begin clinical trials

六月 22, 2017 davesilver 0 Comment

Taipei, Taiwan-headquartered Lumosa Therapeutics Co., Ltd. has announced that its lead drug candidate for acute ischemic stroke, LT3001, has received approval from the US FDA to begin Phase I clinical trials.

Image: OBI Pharma

生物技術製藥

OBI Pharma announces acquisition of cancer drug candidate from Threshold Pharmaceuticals

六月 6, 2017六月 6, 2017 davesilver 0 Comment 生物技術, 製藥

Taipei, Taiwan-headquartered OBI Pharma, Inc., (TPex: 4174), announced last week that an agreement with Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) had been made to acquire TH-3424, a first-in-class novel small-molecule prodrug that selectively targets cancers overexpressing the enzyme aldo-keto reductase 1c3 (AKR1C3).

Photo: Pixabay

生物技術製藥

Taiwan a great location for biotech IPOs, says Aslan Pharma CEO

六月 6, 2017六月 6, 2017 davesilver 0 Comment 生物技術, 製藥

In an interview with finance website Deal Street Asia, Singapore-headquartered drug development firm Asian Pharmaceuticals’ CEO Dr Carl Firth discussed why he took the company public in Taiwan and not Singapore, Europe or the US.